<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>mice, but rarely seen in c-kit-/- mice. In wildtype mice, epithelialabrasion induced an acute inflammatory response with early (3h) andsustained (out to 30h) dilation in the limbal vessels, and significantneutrophil and platelet extravasation. Mice deficient in mast cells (ckit-/-) exhibited early vessel dilation (3h), but this response was notsustained. These mice also showed diminished platelet and neutrophilrecruitment which was accompanied by delayed (6h) epithelialwound closure and significant blunting of basal epithelial celldivision (60% less at 18h post-injury). Neutrophil recruitment waspartially restored in mast cell deficient mice that received asubconjunctival injection of cultured wildtype mast cells 4 days priorto epithelial abrasion. Experiments treating wildtype mice withcromolyn or ketotifen gave results consistent with those in c-kit -/-mice.Conclusions: Collectively, the data suggest mast cells play a pivotalrole in corneal inflammation and wound healing. Specifically, mastcells are needed for sustained limbal vessel dilation and coordinatedneutrophil and platelet recruitment. In the absence of mast cells ortheir degranulation products, the diminished leukocyte recruitmentlikely accounts for the observed reduction in the rate of cornealwound closure and the number of dividing epithelial cells.Commercial Relationships: Alan R. Burns, None; Qiong Liu,None; Zhijie Li, None; Clifton W. Smith, NoneSupport: NIH Grants EY07551, EY017120, EY018239 and NationalNatural Science Foundation of China grants 39970250, 30772387and 81070703.Program Number: 3913 Poster Board Number: D0157Presentation Time: 2:45 PM - 4:30 PMChanges in Mouse <strong>Cornea</strong>l Epithelial Innervation After InjuryLanny Shulman 1 , Samuel D. Hanlon 1 , Paul T. Landry 1 , Clifton W.Smith 2 , Alan R. Burns 1, 2 . 1 College of Optometry, University ofHouston, Houston, TX; 2 Department of Leukocyte Biology, BaylorCollege of Medicine, Houston, TX.Purpose: <strong>Cornea</strong>l epithelial abrasion is associated with nerve injuryand while nerve regeneration in the mouse model can occur quickly,with nerve density recovering by 6 weeks post-injury, the pattern ofthe subbasal nerve plexus is abnormal. Whether nerve regenerationinvolves a change in the number of epithelial leashes and theirdistribution is unclear. An epithelial leash is defined as a group ofsubbasal nerves originating from a deeper stromal nerve. The purposeof this study is to provide a more detailed analysis of epithelial leashnumber and distribution following a central epithelial cornealabrasion.Methods: Anesthetized adult C57BL/6 mice ages 8-10 weeksreceived 2.0 mm wide central corneal epithelial abrasions with anAlger brush. Uninjured age-matched mice served as controls. Micewere euthanized at 2, 4, and 6 weeks post-injury and corneas wereexcised, fixed and incubated in neuronal specific β-III Tubulin taggedwith phycoerythrin; DAPI staining was used to identify cell nuclei.Using a DeltaVision fluorescence microscope, corneal wholemountswere partitioned into three concentric circular zones: a central 1600μm diameter zone, a middle zone extending approximately 800 μmand a peripheral 480 μm zone. Epithelial leash number anddistribution were evaluated using Image J software and a customMatlab program.Results: In the uninjured cornea, epithelial leashes were generallyconfined to the middle (72 ±12) and peripheral zones (17 ±3); veryfew leashes were detected in the central zone (6 ±4). At 2 weeks postinjury,epithelial leash counts in the central zone increased 4-6 foldover age-matched controls and remained elevated at 4 and 6 weekspost-injury. In contrast, there was no significant change in thenumber of leashes in the middle and peripheral zones at 2, 4 or 6weeks post-injury.Conclusions: The data suggest that following a central epithelialabrasion, the greatest increase in epithelial leashes occurs in thecentral zone, which prior to injury had very few leashes. The de novoappearance of epithelial leashes in the central zone contributes to theabnormal patterning of the regenerating subbasal nerve plexus.Commercial Relationships: Lanny Shulman, None; Samuel D.Hanlon, None; Paul T. Landry, None; Clifton W. Smith, None;Alan R. Burns, NoneSupport: NH Grant EY07551; NH Grant EY017120; NH GrantEY018239411 Keratoconus and BiomechanicsWednesday, May 08, 2013 8:30 AM-10:15 AMTCC 303 Paper SessionProgram #/Board # Range: 4069-4075Organizing Section: <strong>Cornea</strong>Program Number: 4069Presentation Time: 8:30 AM - 8:45 AMMutations in the zinc finger protein gene, ZNF469 contribute tothe pathogenesis of keratoconusAndrea L. Vincent 1, 2 , Charlotte Jordan 1, 2 , Bryan Hay 1 , Amanda J.Richards 1 , Charles N. McGhee 1, 2 . 1 Ophthalmology, New ZealandNational Eye Centre, University of Auckland, Auckland, NewZealand; 2 Eye Department, Greenlane Clinical Centre, AucklandDistrict Health Board, Auckland, New Zealand.Purpose: Mutations in the zinc finger protein gene ZNF469 areidentified as one genetic cause for the recessive disorder Brittle<strong>Cornea</strong> syndrome, characterised by spontaneous corneal perforations.GWAS studies have also implicated this gene as a determinant forcentral corneal thickness(CCT). We investigated the geneticcontribution of ZNF469 in a cohort of patients with keratoconus -both familial and sporadic.Methods: Patients with keratoconus were identified and recruitedfrom the University of Auckland special eye clinic, and the EyeDepartment, Auckland District Health Board. If a family history ofkeratoconus was present, family members were recruited andexamined where possible. Following informed consent, allindividuals underwent comprehensive anterior segment examinationincluding corneal topography (Orbscan, Pentacam) and axial length,and a biological sample (venous blood, saliva) collected for DNAextraction.Mutational analysis of both exons of ZNF469 was undertaken usingpolymerase chain reaction, bidirectional Sanger sequencing, and highresolution melting analysis.4 changes detected in the familial cases (Polynesian) were screenedin an ethnically matched population. For each observed change,bioinformatic databases of exome variation were used to determinepresence and frequency, and protein prediction software to determinepathogenicity.Results: Of the 43 probands, at least one probable disease causingvariant was detected in ZNF469 in 20 (46%), and in 5, two variantswere observed (11.6% - 4 compound heterozygotes, 1 homozygote).Fourteen non-synonymous missense SNPs were observed, 6 of whichwere not previously documented in any population-based geneticvariant database. For the sporadic cases, 12/32 had one change, and3/32, 2 changes. Of the familial cases 3/11 probands had one change,and 2 of the 11 had 2 changes, although only heterozygous changessegregated with disease.Conclusions: Rare missense mutations in ZNF469, predicted to bepathogenic, are found heterozygously at a frequency of 46% in a©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
<strong>ARVO</strong> 2013 Annual Meeting Abstracts by Scientific Section/Group - <strong>Cornea</strong>keratoconus population. ZNF469 is shown to be associated withCCT, and likely to play a role in the synthesis and/or organization ofcorneal collagen fibres. The findings in this cohort suggest thepathogenic changes observed either genetically predispose towards a“thin” cornea, which then becomes keratoconic, or are directlypathogenic.Commercial Relationships: Andrea L. Vincent, OphthalmicResearch Institute of Australia (S); Charlotte Jordan, None; BryanHay, None; Amanda J. Richards, None; Charles N. McGhee, Codatherapeutics (C)Support: Save Sight Society New Zealand, Maurice and PhyllisPaykel Trust, PBRF University of Auckland. Aucland MedicalResearch FoundationProgram Number: 4070Presentation Time: 8:45 AM - 9:00 AMMatrix Metalloproteinase-9 drives disease progression ofKeratoconusashwini ranganath, Rohit Shetty, Sharon D'Souza, KareeshmaWadia, Debashish Das, Arkasubhra Ghosh. cornea and refractivesurgery, Narayana Nethralaya eye hospital, Bangalore, India.Purpose: Keratoconus is a corneal thinning disorder of unknownetiology for which no drugs or therapies are available currently.Furthermore, the exact cause of stromal thinning is not clear. Matrixmetalloproteinases are upregulated during matrix remodeling andcause degradation of various types of collagen. MMP9 has beendemonstrated to degrade typeI and IV collagen fibers in cancer. Thisactivity is regulated by cytokine Interleukin 6(IL6). We thereforeasked whether MMP9 is upregulation in keratoconus correlates toincreasing stages of disease and depends on abnormal IL6 levels. Wequantified levels of MMP9 and IL6 in tear films of keratoconuspatients and correlated with severity of disease. To validate ourhypothesis we investigated effect of topical CsA(cyclosporineA)treatment in keratoconus as it has been demonstrated to inhibitMMP9 and has been approved for treatment of allergic eye disease.Methods: 64 eyes with keratoconus of varying severity wereincluded. This study and on label use od CsA to treat associated withkeratoconus was approved by Narayana Nethralaya IRB.Keratoconus was graded based on topographic criteria ofKeratoconus Severity Index using steep K into 56D. Tear samples were collected from lower fornix withcapillary tubes. Levels of MMP-9 and IL6 in each sample weremeasured by ELISA and were correlated with severity ofkeratoconus. 10 patients with progressive keratoconus were treatedwith topical CsA 0.05% and topography was analyzed pre and posttreatment (6 months and 1 year) to evaluate stability of keratoconus.Results: Mean MMP9 (Normal 3.9-8.3 ng/ml) and IL6 (normal 1-4.1) respectively were 42.45 and 1.03 in 56 D group.Of 10 patients treated with CsA, 8 showed stabilization ofkeratoconus, and 6 had flattening of keratometry ranging from 0.5-1.7D, 6 months to 1 year post treatment.Conclusions: Significantly higher levels of MMP9 and marginallyhigher levels of IL6 were detected in tear samples of keratoconuseyes, and their levels positively correlated with severity ofkeratoconus. Inhibiting MMP9 locally in cornea using CsA halteddisease progression and even reduced the disease in few cases. Thissuggests MMP9 is an important factor driving keratoconuspathophysiology. Also, topical CsA may be an effective diseasemodifying agent in keratoconus management.Commercial Relationships: ashwini ranganath, None; RohitShetty, None; Sharon D'Souza, None; Kareeshma Wadia, None;Debashish Das, None; Arkasubhra Ghosh, NoneClinical Trial: J0002GQQProgram Number: 4071Presentation Time: 9:00 AM - 9:15 AMNovel proteins and metabolites for the identification ofKeratoconus diseaseDimitrios Karamichos 1, 2 , Jesper Hjortdal 4 , Audrey E. Hutcheon 1, 2 ,John M. Asara 3 , James D. Zieske 1, 2 . 1 Schepens Eye ResearchInstitute/MEE, Boston, MA; 2 Department of Ophthalmology,Harvard Medical School, Boston, MA; 3 Division of SignalTransduction/Mass Spectrometry Core, Beth Israel DeaconessMedical Center, Harvard Medical School, Boston, MA; 4 Departmentof Ophthalmology, Aarhus University Hospital, Aarhus C, Denmark.Purpose: Keratoconus (KC) is a degenerative disorder of the corneawhere structural changes cause it to thin, protrude and assume a moreconical shape. Prevalence of the disease ranges from 4-600/100,000people and can result in severe vision loss. The exact cause isuncertain, and patients with advanced KC require surgery to maintainvision. One of the major clinical problems with treating the disease isthere are no methods for early detection. Also, there currently are nomodels available to investigate and understand the root causes of thedisease.Methods: In vitro, human corneal fibroblasts (HCF), keratocytes,and keratoconus cells (HKC) were isolated and cultured. Cells werestimulated with a stable Vitamin C (VitC) derivative for 4 weeks,allowing them to secrete a self-assembled matrix. In vivo, humantears were collected from healthy and KC individuals. All sampleswere processed for metabolomic and proteomic analyses using LC-MS/MS. In vitro samples were also processed for indirectimmunofluorescenceand transmission electron microscopy.Results: We identified more than 250 different metabolites of which>50 were differentially regulated between groups. Two of them,Lactate and Arginine, have been previously linked to corneal edemaand thinning. In vitro, Lactate levels were elevated 4 fold in HKCswhen compared to keratocytes and 2 fold when compared to HCFs;however, Arginine levels were significantly reduced in both HCFsand HKCs as compared to keratocytes. In addition, Glutathione levelswere reduced when compared to keratocytes, significantly in HCFsand 2 fold in HKCs. In vivo, these metabolites were regulatedsimilarly, Lactate levels increased and Arginine and Glutathionedecreased in KC patients. We also identified more than 200 proteinsin human tears, some of which may serve as new KC defect markers(i.e. Gross cystic disease fluid protein 15 (GCDFP-15) decreased by 2fold and Lactate dehydrogenase isozyme (LDH) was significantlyelevated in KC patients). Critically, our proteomics andmetabolomics agree and are cross-validating since LDH convertspyruvate to lactate.Conclusions: Overall, we have developed a novel in vitro model thatallows for the study of proteins and metabolites, both in vitro and invivo, which may help understand the root problem of KC and mayallow for identification of markers of KC disease.Commercial Relationships: Dimitrios Karamichos, None; JesperHjortdal, Carl Zeiss Meditec (R); Audrey E. Hutcheon, None;John M. Asara, None; James D. Zieske, NoneSupport: NIH Grant EY020886, NIH Grant EY03790 (Core) andHMS/HSDM Alice J. Adler Fellowship: The Eleanor and MilesShore 50th Anniversary Fellowships for Scholars in MedicineProgram Number: 4072Presentation Time: 9:15 AM - 9:30 AM©2013, Copyright by the Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Go to iovs.org to access the version of record. For permissionto reproduce any abstract, contact the <strong>ARVO</strong> Office at arvo@arvo.org.
- Page 2 and 3:
ARVO 2013 Annual Meeting Abstracts
- Page 4 and 5:
ARVO 2013 Annual Meeting Abstracts
- Page 6 and 7:
ARVO 2013 Annual Meeting Abstracts
- Page 8 and 9:
ARVO 2013 Annual Meeting Abstracts
- Page 10:
ARVO 2013 Annual Meeting Abstracts
- Page 13 and 14:
ARVO 2013 Annual Meeting Abstracts
- Page 16 and 17:
ARVO 2013 Annual Meeting Abstracts
- Page 18 and 19:
ARVO 2013 Annual Meeting Abstracts
- Page 20 and 21:
ARVO 2013 Annual Meeting Abstracts
- Page 22 and 23:
ARVO 2013 Annual Meeting Abstracts
- Page 24 and 25:
ARVO 2013 Annual Meeting Abstracts
- Page 26 and 27:
ARVO 2013 Annual Meeting Abstracts
- Page 28 and 29:
ARVO 2013 Annual Meeting Abstracts
- Page 30 and 31:
ARVO 2013 Annual Meeting Abstracts
- Page 32 and 33:
ARVO 2013 Annual Meeting Abstracts
- Page 34 and 35:
ARVO 2013 Annual Meeting Abstracts
- Page 36 and 37:
ARVO 2013 Annual Meeting Abstracts
- Page 38 and 39:
ARVO 2013 Annual Meeting Abstracts
- Page 40 and 41:
ARVO 2013 Annual Meeting Abstracts
- Page 42 and 43:
ARVO 2013 Annual Meeting Abstracts
- Page 44 and 45:
ARVO 2013 Annual Meeting Abstracts
- Page 46 and 47:
ARVO 2013 Annual Meeting Abstracts
- Page 48 and 49:
ARVO 2013 Annual Meeting Abstracts
- Page 50 and 51:
ARVO 2013 Annual Meeting Abstracts
- Page 52 and 53:
ARVO 2013 Annual Meeting Abstracts
- Page 54 and 55:
ARVO 2013 Annual Meeting Abstracts
- Page 56 and 57:
ARVO 2013 Annual Meeting Abstracts
- Page 58 and 59:
ARVO 2013 Annual Meeting Abstracts
- Page 60 and 61:
ARVO 2013 Annual Meeting Abstracts
- Page 62 and 63:
ARVO 2013 Annual Meeting Abstracts
- Page 64 and 65:
ARVO 2013 Annual Meeting Abstracts
- Page 66 and 67:
ARVO 2013 Annual Meeting Abstracts
- Page 68 and 69:
ARVO 2013 Annual Meeting Abstracts
- Page 70 and 71:
ARVO 2013 Annual Meeting Abstracts
- Page 72 and 73:
ARVO 2013 Annual Meeting Abstracts
- Page 74 and 75:
ARVO 2013 Annual Meeting Abstracts
- Page 76 and 77:
ARVO 2013 Annual Meeting Abstracts
- Page 78 and 79:
ARVO 2013 Annual Meeting Abstracts
- Page 80 and 81:
ARVO 2013 Annual Meeting Abstracts
- Page 82 and 83:
ARVO 2013 Annual Meeting Abstracts
- Page 84 and 85:
ARVO 2013 Annual Meeting Abstracts
- Page 86 and 87:
ARVO 2013 Annual Meeting Abstracts
- Page 88 and 89:
ARVO 2013 Annual Meeting Abstracts
- Page 90 and 91:
ARVO 2013 Annual Meeting Abstracts
- Page 92 and 93:
ARVO 2013 Annual Meeting Abstracts
- Page 94 and 95:
ARVO 2013 Annual Meeting Abstracts
- Page 96 and 97:
ARVO 2013 Annual Meeting Abstracts
- Page 98 and 99:
ARVO 2013 Annual Meeting Abstracts
- Page 100 and 101:
ARVO 2013 Annual Meeting Abstracts
- Page 102 and 103:
ARVO 2013 Annual Meeting Abstracts
- Page 104 and 105:
ARVO 2013 Annual Meeting Abstracts
- Page 106 and 107:
ARVO 2013 Annual Meeting Abstracts
- Page 108 and 109:
ARVO 2013 Annual Meeting Abstracts
- Page 110 and 111:
ARVO 2013 Annual Meeting Abstracts
- Page 112 and 113:
ARVO 2013 Annual Meeting Abstracts
- Page 114 and 115:
ARVO 2013 Annual Meeting Abstracts
- Page 116 and 117:
ARVO 2013 Annual Meeting Abstracts
- Page 118 and 119:
ARVO 2013 Annual Meeting Abstracts
- Page 120 and 121:
ARVO 2013 Annual Meeting Abstracts
- Page 122 and 123:
ARVO 2013 Annual Meeting Abstracts
- Page 124 and 125:
ARVO 2013 Annual Meeting Abstracts
- Page 126 and 127:
ARVO 2013 Annual Meeting Abstracts
- Page 128 and 129:
ARVO 2013 Annual Meeting Abstracts
- Page 130 and 131:
ARVO 2013 Annual Meeting Abstracts
- Page 132 and 133:
ARVO 2013 Annual Meeting Abstracts
- Page 134 and 135:
ARVO 2013 Annual Meeting Abstracts
- Page 136 and 137:
ARVO 2013 Annual Meeting Abstracts
- Page 138 and 139:
ARVO 2013 Annual Meeting Abstracts
- Page 140 and 141:
ARVO 2013 Annual Meeting Abstracts
- Page 142 and 143:
ARVO 2013 Annual Meeting Abstracts
- Page 144 and 145:
ARVO 2013 Annual Meeting Abstracts
- Page 146 and 147:
ARVO 2013 Annual Meeting Abstracts
- Page 148 and 149:
ARVO 2013 Annual Meeting Abstracts
- Page 150 and 151:
ARVO 2013 Annual Meeting Abstracts
- Page 152 and 153:
ARVO 2013 Annual Meeting Abstracts
- Page 154 and 155:
ARVO 2013 Annual Meeting Abstracts
- Page 156 and 157:
ARVO 2013 Annual Meeting Abstracts
- Page 158 and 159:
ARVO 2013 Annual Meeting Abstracts
- Page 160 and 161:
ARVO 2013 Annual Meeting Abstracts
- Page 162 and 163:
ARVO 2013 Annual Meeting Abstracts
- Page 164 and 165:
ARVO 2013 Annual Meeting Abstracts
- Page 166 and 167:
ARVO 2013 Annual Meeting Abstracts
- Page 168 and 169:
ARVO 2013 Annual Meeting Abstracts
- Page 170 and 171:
ARVO 2013 Annual Meeting Abstracts
- Page 172 and 173:
ARVO 2013 Annual Meeting Abstracts
- Page 174 and 175:
ARVO 2013 Annual Meeting Abstracts
- Page 176 and 177:
ARVO 2013 Annual Meeting Abstracts
- Page 178 and 179:
ARVO 2013 Annual Meeting Abstracts
- Page 180 and 181:
ARVO 2013 Annual Meeting Abstracts
- Page 182 and 183:
ARVO 2013 Annual Meeting Abstracts
- Page 184 and 185:
ARVO 2013 Annual Meeting Abstracts
- Page 186 and 187:
ARVO 2013 Annual Meeting Abstracts
- Page 188 and 189:
ARVO 2013 Annual Meeting Abstracts
- Page 190 and 191:
ARVO 2013 Annual Meeting Abstracts
- Page 192 and 193:
ARVO 2013 Annual Meeting Abstracts
- Page 194 and 195:
ARVO 2013 Annual Meeting Abstracts
- Page 196 and 197:
ARVO 2013 Annual Meeting Abstracts
- Page 198 and 199:
ARVO 2013 Annual Meeting Abstracts
- Page 200 and 201:
ARVO 2013 Annual Meeting Abstracts
- Page 202 and 203:
ARVO 2013 Annual Meeting Abstracts
- Page 204 and 205:
ARVO 2013 Annual Meeting Abstracts
- Page 206 and 207: ARVO 2013 Annual Meeting Abstracts
- Page 208 and 209: ARVO 2013 Annual Meeting Abstracts
- Page 210 and 211: ARVO 2013 Annual Meeting Abstracts
- Page 212 and 213: ARVO 2013 Annual Meeting Abstracts
- Page 214 and 215: ARVO 2013 Annual Meeting Abstracts
- Page 216 and 217: ARVO 2013 Annual Meeting Abstracts
- Page 218 and 219: ARVO 2013 Annual Meeting Abstracts
- Page 220 and 221: ARVO 2013 Annual Meeting Abstracts
- Page 222 and 223: ARVO 2013 Annual Meeting Abstracts
- Page 224 and 225: ARVO 2013 Annual Meeting Abstracts
- Page 226 and 227: ARVO 2013 Annual Meeting Abstracts
- Page 228 and 229: ARVO 2013 Annual Meeting Abstracts
- Page 230 and 231: ARVO 2013 Annual Meeting Abstracts
- Page 232 and 233: ARVO 2013 Annual Meeting Abstracts
- Page 234 and 235: ARVO 2013 Annual Meeting Abstracts
- Page 236 and 237: ARVO 2013 Annual Meeting Abstracts
- Page 238 and 239: ARVO 2013 Annual Meeting Abstracts
- Page 240 and 241: ARVO 2013 Annual Meeting Abstracts
- Page 242 and 243: ARVO 2013 Annual Meeting Abstracts
- Page 244 and 245: ARVO 2013 Annual Meeting Abstracts
- Page 246 and 247: ARVO 2013 Annual Meeting Abstracts
- Page 248 and 249: ARVO 2013 Annual Meeting Abstracts
- Page 250 and 251: ARVO 2013 Annual Meeting Abstracts
- Page 252 and 253: ARVO 2013 Annual Meeting Abstracts
- Page 254 and 255: ARVO 2013 Annual Meeting Abstracts
- Page 258 and 259: ARVO 2013 Annual Meeting Abstracts
- Page 260 and 261: ARVO 2013 Annual Meeting Abstracts
- Page 262 and 263: ARVO 2013 Annual Meeting Abstracts
- Page 264 and 265: ARVO 2013 Annual Meeting Abstracts
- Page 266 and 267: ARVO 2013 Annual Meeting Abstracts
- Page 268 and 269: ARVO 2013 Annual Meeting Abstracts
- Page 270 and 271: ARVO 2013 Annual Meeting Abstracts
- Page 272 and 273: ARVO 2013 Annual Meeting Abstracts
- Page 274 and 275: ARVO 2013 Annual Meeting Abstracts
- Page 276 and 277: ARVO 2013 Annual Meeting Abstracts
- Page 278 and 279: ARVO 2013 Annual Meeting Abstracts
- Page 280 and 281: ARVO 2013 Annual Meeting Abstracts
- Page 282 and 283: ARVO 2013 Annual Meeting Abstracts
- Page 284 and 285: ARVO 2013 Annual Meeting Abstracts
- Page 286 and 287: ARVO 2013 Annual Meeting Abstracts
- Page 288 and 289: ARVO 2013 Annual Meeting Abstracts
- Page 290 and 291: ARVO 2013 Annual Meeting Abstracts
- Page 292 and 293: ARVO 2013 Annual Meeting Abstracts
- Page 294 and 295: ARVO 2013 Annual Meeting Abstracts
- Page 296 and 297: ARVO 2013 Annual Meeting Abstracts
- Page 298 and 299: ARVO 2013 Annual Meeting Abstracts
- Page 300 and 301: ARVO 2013 Annual Meeting Abstracts
- Page 302 and 303: ARVO 2013 Annual Meeting Abstracts
- Page 304 and 305: ARVO 2013 Annual Meeting Abstracts
- Page 306 and 307:
ARVO 2013 Annual Meeting Abstracts
- Page 308 and 309:
ARVO 2013 Annual Meeting Abstracts
- Page 310 and 311:
ARVO 2013 Annual Meeting Abstracts
- Page 312 and 313:
ARVO 2013 Annual Meeting Abstracts
- Page 314 and 315:
ARVO 2013 Annual Meeting Abstracts
- Page 316 and 317:
ARVO 2013 Annual Meeting Abstracts
- Page 318 and 319:
ARVO 2013 Annual Meeting Abstracts
- Page 320 and 321:
ARVO 2013 Annual Meeting Abstracts
- Page 322 and 323:
ARVO 2013 Annual Meeting Abstracts
- Page 324 and 325:
ARVO 2013 Annual Meeting Abstracts
- Page 326 and 327:
ARVO 2013 Annual Meeting Abstracts
- Page 328 and 329:
ARVO 2013 Annual Meeting Abstracts
- Page 330 and 331:
ARVO 2013 Annual Meeting Abstracts
- Page 332 and 333:
ARVO 2013 Annual Meeting Abstracts
- Page 334 and 335:
ARVO 2013 Annual Meeting Abstracts
- Page 336 and 337:
ARVO 2013 Annual Meeting Abstracts
- Page 338 and 339:
ARVO 2013 Annual Meeting Abstracts
- Page 340 and 341:
ARVO 2013 Annual Meeting Abstracts
- Page 342 and 343:
ARVO 2013 Annual Meeting Abstracts
- Page 344 and 345:
ARVO 2013 Annual Meeting Abstracts
- Page 346 and 347:
ARVO 2013 Annual Meeting Abstracts
- Page 348 and 349:
ARVO 2013 Annual Meeting Abstracts
- Page 350 and 351:
ARVO 2013 Annual Meeting Abstracts
- Page 352 and 353:
ARVO 2013 Annual Meeting Abstracts
- Page 354 and 355:
ARVO 2013 Annual Meeting Abstracts
- Page 356 and 357:
ARVO 2013 Annual Meeting Abstracts
- Page 358 and 359:
ARVO 2013 Annual Meeting Abstracts
- Page 360 and 361:
ARVO 2013 Annual Meeting Abstracts
- Page 362 and 363:
ARVO 2013 Annual Meeting Abstracts
- Page 364 and 365:
ARVO 2013 Annual Meeting Abstracts
- Page 366 and 367:
ARVO 2013 Annual Meeting Abstracts
- Page 368 and 369:
ARVO 2013 Annual Meeting Abstracts
- Page 370 and 371:
ARVO 2013 Annual Meeting Abstracts
- Page 372 and 373:
ARVO 2013 Annual Meeting Abstracts
- Page 374 and 375:
ARVO 2013 Annual Meeting Abstracts
- Page 376 and 377:
ARVO 2013 Annual Meeting Abstracts
- Page 378 and 379:
ARVO 2013 Annual Meeting Abstracts
- Page 380 and 381:
ARVO 2013 Annual Meeting Abstracts
- Page 382 and 383:
ARVO 2013 Annual Meeting Abstracts